Dietary supplementation of vitamin D is commonly recommended to patients with multiple sclerosis. We recently found that high-dose of the hormonally active 1,25-dihydroxyvitamin-D3 (1,25D) promotes myelin repair in the cuprizone model for de- and remyelination. In the present study, we quantified 5062 proteins, of which 125 were differentially regulated in brain tissue from 1,25D treated mice during remyelination, compared to placebo. Proteins upregulated in the early remyelination phase were involved in calcium binding, e.g. calretinin (>1.3 fold, p < 0.005), S10A5 and secretagogin, and involved in mitochondrial function, e.g. NADH-ubiquinone oxidoreductase chain 3, and acyl-coenzyme A synthetase. Calretinin, S10A5 and secretagogin expression levels were characterized using immunohistochemistry. Calretinin immunoreactivity was significantly increased (>3 fold, p = 0.016) in the medial septal nuclei of 1,25D treated mice in the early remyelination phase. Our results indicate that vitamin D may influence remyelination by mechanisms involving an increase in calretinin expression and potentially other calcium binding proteins.
Keywords: 1,25-Dihydroxyvitamin D3 (PubChem CID 5280453); 1,25-Dihydroxyvitamin-D(3); Biscyclohexanone oxaldihydrazone (cuprizone) (PubChem CID 9723); Calretinin; Cuprizone; Immunohistochemistry; Multiple sclerosis; Quantitative proteomics; Remyelination; S10A5; Secretagogin; TMT-Labeling.
Copyright © 2017 Elsevier Ltd. All rights reserved.